Published in Cancer Weekly, October 26th, 2004
"However, significant understaging jeopardizes long-term survival and improvements and radical surgery represents a provocative alternative," reported F.J. Bianco and colleagues.
The researchers reported, "We evaluated disease-free and cancer-specific survival (CSS) in our cohort of patients with high-grade T1 tumors. A total of 318 patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.